Seeking Alpha

TG Therapeutics doesn't know why stock is down

  • For those looking for the catalyst behind the double-digit decline in shares of TG Therapeutics (TGTX -14.5%), don't ask the company.
  • "While [we] do not typically comment on unusual market activity [we are] not aware of any developments that would merit such trading activity," TGTX says, before reiterating that the next milestones are the initiation of combo trials for TG-1101 and BTK and/or PI3K delta inhibitors, and the presentation of Phase 1 data for TGR-1202. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|